Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis-Reference-Cited by-同舟云学术

Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis

Published:2022-12 Issue:6 Volume:82 Page:584-598
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Yanagisawa Takafumi,Rajwa Pawel,Thibault Constance,Gandaglia Giorgio,Mori Keiichiro,Kawada Tatsushi,Fukuokaya Wataru,Shim Sung Ryul,Mostafaei Hadi,Motlagh Reza Sari,Quhal Fahad,Laukhtina Ekaterina,Pallauf Maximilian,Pradere Benjamin,Kimura Takahiro,Egawa Shin,Shariat Shahrokh F.

Funder

European Association of Urology

Publisher

Elsevier BV

Subject

Urology

Reference40 articles.

1. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer;Armstrong;J Clin Oncol,2019

2. Apalutamide for metastatic, castration-sensitive prostate cancer;Chi;N Engl J Med,2019

3. Enzalutamide with standard first-line therapy in metastatic prostate cancer;Davis;N Engl J Med,2019

4. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial;Fizazi;Lancet Oncol,2019

5. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial;Gravis;Eur Urol,2016

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long acting injectables for the treatment of prostate cancer;Journal of Drug Delivery Science and Technology;2024-10

2. Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer;Steroids;2024-10

3. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis;Prostate Cancer and Prostatic Diseases;2024-09-05

4. Creatine supplementation does not add to resistance training effects in prostate cancer patients under androgen deprivation therapy: a double-blind randomized trial;Journal of Science and Medicine in Sport;2024-09

5. Implementation of fracture risk assessment in men with prostate cancer requiring long-term androgen deprivation therapy: a systematic scoping review using the i-PARIHS implementation framework;Journal of Cancer Survivorship;2024-08-14